Business
InMed Receives CTA Approval for Second Phase 1 Clinical Trial with INM-755
InMed Receives CTA Approval for Second Phase 1 Clinical Trial with INM-755 Canada ...
About this update from Infield Minerals Corp
[{"type":"text","content":"\n\n\n\nInMed Receives CTA Approval for Second Phase 1 Clinical Trial with INM-755\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\n\nCanada NewsWire\nVANCOUVER, April 30, 2020\n\n\n\nVANCOUVER, April 30, 2020 /CNW/ - InMed Pharmaceuticals Inc. (\"InMed\" or the \"Company\") (TSX: IN; OTCQX: IMLFF), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol (\"CBN\"), today announced it has received regulatory and ethics board approval of its Clinical Trial Application (\"CTA\") to conduct its second Phase 1 trial with INM-755.\nThe 755-102-HV clinical trial is a randomized, double-blind, vehicle-controlled, Phase 1 study designed to evaluate the safety and tolerability of INM-755 cream applied daily on epidermal wounds in healthy volunteers. Two strengths of INM-755 cream will be evaluated in 8 adult subjects over a 14-day treatment period. INM-755 is a CBN cream intended as a topical therapy to treat epidermolysis bullosa (\"EB\") and potentially other dermatological diseases.\n\"We are pleased with the successful CTA review process and we look forward to advancing INM-755 into this second Phase 1 trial,\" commented Eric A. Adams, President and CEO of InMed Pharmaceuticals. \"Despite the current constraints presented by the pandemic, our team continues to prepare for study initiation to ensure that we will be poised to commence enrollment at the earliest possible opportunity.\"\nThe Dutch national government has announced that a few pandemic-related restrictions will be lifted soon but most restrictions will remain in place until at least May 20th.  The Centre for Human Drug Research, where the 755-102-HV trial will be conducted, is planning for the initiation of new clinical trials once permitted by the government. The Company will provide an update on the initiation of 755-102-HV when there is more certainty around timing.  \nAbout InMed: InMed Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of cannabino...